Positive results announced for Parkinson’s treatment ARV-102
Biotechnology company Arvinas has announced positive results for its Phase I clinical trial of ARV-102 in Parkinson’s disease.
The results, presented at the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu, show positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase I clinical trials evaluating ARV-102, an oral, brain-penetrant investigational PROTAC degrader of leucine-rich repeat kinase 2 (LRRK2).
The data suggest that ARV-102 was generally well tolerated at single doses up to 200mg and multiple daily doses up to 80 mg, with no discontinuations due to adverse events (AEs) or serious adverse events (SAEs) observed in the study population.
ARV-102 exposure increased in a dose-dependent manner in plasma and CSF, the latter indicating brain penetration, according to the findings. The data also show that repeated daily doses of more than 20 mg resulted in over 90% reductions of LRRK2 protein in peripheral blood mononuclear cells (PBMCs) and more than 50% reductions in CSF.
“We are particularly excited by the CSF proteomics results, which demonstrate modulation of lysosomal and microglial pathways that are known to be associated with neurodegenerative diseases,” said Noah Berkowitz, Chief Medical Officer of Arvinas. “We believe these findings support the intensified development of ARV-102 in ongoing studies of patients with Parkinson’s disease, and in future studies of patients with progressive supranuclear palsy.”
The Phase I trial in patients with Parkinson’s disease included 15 patients treated with ARV-102 and four patients treated with placebo. In the trial, single doses of ARV-102 (50mg or 200mg) were well tolerated, with only mild treatment-related AEs including headache, diarrhoea, and nausea.
“To our knowledge, this is the first time an investigational LRRK2 therapy has, at 14 days in healthy volunteers, shown effects on distal pathway biomarkers in CSF that are elevated in patients with LRRK2 Parkinson’s disease,” said John Houston, Chairperson, Chief Executive Officer, and President at Arvinas. “These data highlight the potential of PROTAC-mediated LRRK2 degradation, encouraging further development that could benefit patients in the future.”
Arvinas plans to present initial data from a multiple dose cohort of the Phase I clinical trial in patients with Parkinson’s disease (ARV-102-103) in 2026. Pending data from the multiple dose cohort and investigational new drug (IND) clearance, Arvinas intends to initiate a Phase Ib trial in patients with progressive supranuclear palsy in the first half of 2026.
Bruno Quinney, Content Team, DDW
